• Papers

  more

• [1] Ambiguous guideline recommendations harm patient care
• [2] The social distribution of quality adjusted life expectancy (QALE) among social deprivation subgroups in China
• • [3] Measuring health spillover effects in household members of adolescents and elderly individuals with health issues in China
  • [4] Does DRG-based payment lead to unintended effects on care quality? A case under global budget with price adjustment in China
  • [5] Can DRG payment under global budget with price adjustment curb the soaring healthcare costs? Insights from China's reform and its underlying mechanism
  • [6] Evaluation of measurement properties of the Health Assessment Questionnaire-Disability Index (HAQ-DI) among gout patients in China
  • [7] How Does Disease Severity Affect Clinical Outcomes and Economic Burden of Patients with COPD -- A Retrospective Population-Based Cohort Study in Tianjin, China
  • [8] Development of the County-Level Social Deprivation Index 2020 and Its Association With Health Outcomes in China.
  • [9] Assessing the economic burden and health-related quality of life in chinese patients with fibrodysplasia ossificans progressiva: a questionnaire survey analysis
  • [10] Impact of pooled procurement of medicines on patient adherence and economic burden: evidence from China
  • [11] Disutility of Treatment-related Attributes for Type 2 Diabetes Mellitus: A Systematic Review
  • [12] Are There Differences in Health State Preferences between Urban and Rural Respondents? A Comparison using Time Trade-off and Discrete Choice Experiment
  • [13] Deriving Health Utility Values using Mapping Methods among Chinese Population: A Systematic Review
  • [14] Testing the unintended cost effects of health policies for generic substitutions: the case of China's National Volume-Based Procurement (NVBP) policy
  • [15] Entecavir for children and adults with chronic hepatitis B
  • [16] Do machine learning approaches perform better than regression models in mapping studies? A systematic review
  • [17] The generic version of China Health Related Outcomes Measures (CHROME-G): Psychometric testing and comparative performance with the EQ-5D-5L and SF-6Dv2 among the Chinese general population
  • [18] Is the Use of Unanchored Matching-Adjusted Indirect Comparison Always uperior to Naïve Indirect Comparison on Survival Outcomes? A Simulation Study
  • [19] Efficiency must not compromise trustworthiness in rating certainty and formulating recommendations in AI era
  • [20] Efficacy, Safety, and Treatment Burden of Aflibercept 2 mg and Ranibizumab in Retinal Vein Occlusion: A Systematic Review and Meta-Analysis
  • [21] Enhancing the Interpretation of Continuous Outcomes and Subgroup Analyses in Systematic Reviews
  • [22] Impact of China’s national volume-based procurement on drug procurement price, volume, and expenditure: an interrupted time series analysis in Tianjin
  • [23] Incorporating absolute effects to enrich interpretation of findings from meta-analyses
  • [24] Diversity when interpreting evidence in network meta-analyses (NMAs) on similar topics: an example case of NMAs on diabetic macular oedema
  • [25] Can case-based payment contain healthcare costs? - A curious case from China
  • [26] Cost Effectiveness of the First-in-Class ARNI (Sacubitril/Valsartan) for the Treatment of Essential Hypertension in a Chinese Setting
  • [27] Policy Updates on Access to and Affordability of Innovative Medicines in China
  • [28] Estimation of the cost-effective threshold of a quality-adjusted life year in China based on the value of statistical life
  • [29] China Health Related Outcomes Measures (CHROME): Development of a New Generic Preference-Based Measure for the Chinese Population
  • [30] How Do Treatment Preferences of Patients With Cancer Compare With Those of Oncologists and Family Members? Evidence From a Discrete Choice Experiment in China
  • [31] Incorporating future unrelated medical costs in cost-effectiveness analysis in China
  • [32] Eliciting SF-6Dv2 Health State Utilities Using An Anchored Best-Worst Scaling Technique
  • [33] Valuation of SF-6Dv2 Health States in China Using Time Trade-off and Discrete-Choice Experiment with a Duration Dimension
  • [34] Do discrete choice experiments approaches perform better than time trade-off in eliciting health state utilities? Evidence from SF-6Dv2 in China
  • [35] The impact of China’s National Essential Medicine Policy and its implications for urban outpatients: a multivariate difference-in-differences study
  • [36] Expert Consensus on Embedding Pharmacoeconomic Evaluation into Clinical Trials (2024 Edition)
  • [37] Empirical Exploration on the Formulation Rules of Medical Insurance Payment Standards for Non‑selected Drugs under Volume‑based Procurement
  • [38] Willingness‑to‑pay for Oral Antidiabetic Drugs among Chinese Patients with Type 2 Diabetes: A Discrete Choice Experiment
  • [39] Empirical Study on Current Pharmacotherapy Status of Patients with Severe Asthma Based on Real‑world Data
  • [40] Review of Measurement Methods for Discount Rates in Pharmacoeconomic Evaluation
  • [41] Epidemiology and Disease Burden Analysis of Patients with Nodular Prurigo Based on Real‑world Data
  • [42] Methodological Review and Application Selection of Indirect Treatment Comparisons Using Patient‑Level Data
  • [43] Application and Prospect of Pharmacoeconomics in Promoting Rational Clinical Medication
  • [44] Methods and Research Progress of Economic Evaluation Incorporating Equity Information
  • [45] Impacts of Basic Medical Insurance Reimbursement Policies on Treatment Level and Costs among Adult Patients with Hemophilia A in China
  • [46] Reflections on Pharmaceutical Price Formation and Payment Standards under Universal Health Insurance
  • [47] Prevalence of Chronic Complications and Per‑visit Medical Costs among Patients with Type 2 Diabetes in China
  • [48] Application of Real‑world Evidence in UK Pharmaceutical Access Agreements: A Case Study of CAR‑T Products
  • [49] Medical Big Data‑Driven Pharmacoeconomic Research from the Perspective of New‑quality Productivity
  • [50] Research on Key Technologies of Real‑world Data for Pharmaceutical Economic Value Evaluation
  • [51] Payment Policies of High‑Value Innovative Medical Technologies under U.S. DRGs and Implications
  • [52] Real-world Study on the Current Status of Antithrombotic Pharmacotherapy among Patients with Chronic Coronary Syndrome in Tianjin
  • [53] Evaluation of Capitation Payment Policy for Hepatitis C under Basic Medical Insurance in Tianjin
  • [54] Introduction and Case Application of Unanchored Matching-Adjusted Indirect Comparison Method
  • [55] Analysis on Implementation Status of China’s Outpatient Chronic Disease Security System
  • [56] Review and Implications on the Development of Health State Classification System for the EQ‑HWB Instrument
  • [57] Study on Fracture Incidence and Related Medical Costs among Postmenopausal Women with Osteoporosis
  • [58] Incidence of Chronic Complications and Related Medical Costs in Newly Diagnosed Type 2 Diabetic Patients in Tianjin
  • [59] A Comparison of DRG Grouping Strategies and Payment Standard Definition at Home and Abroad
  • [60] Empirical Study on Changes in Pharmaceutical Price Levels in China
  • [61] A review of generic health utility measures at home and abroad

• Books

  more

• [1] China Guidelines for Pharmacoeconomic Evaluations, 2025 (Chinese‑English Version)
• [2] China Guidelines for Pharmacoeconomic Evaluations: A Manual（2022）
• • [3] China Guidelines for Pharmacoeconomic Evaluations, 2020 (Chinese‑English Version)
  • [4] Development and Application of Pharmacoeconomics. Theory and Practice of the Essential Medicines System
  • [5] Cost‑Effectiveness Analysis in Healthcare

• Patents
• [1] Descriptive System and Value Set of the Self‑completed Standalone Simplified Chinese Version of SF‑6Dv2

• Honors & Awards

  more

• [1] Young and Middle‑Aged Leading Talents for Scientific and Technological Innovation, Tianjin Innovative Talent Promotion Program (2020)
• [2] Excellent Communist Party Member in Tianjin Education System
• • [3] Excellent Teacher of Tianjin Municipality
  • [4] Top Ten Outstanding Youths, Tianjin University
  • [5] First Prize of the National Service Industry Science and Technology Innovation Award issued by the China General Chamber of Commerce